International Stem Cell Corp., a clinical stage biotech company developing novel stem cell-based therapies, has signed a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health to conduct phase I/IIa clinical trial, dose escalation trial of … Continue reading →

Parkinson’s disease is a progressive movement disorder, meaning that symptoms continue to get worse over time. Approximately one million people in the US are living with this disease. While there is currently no cure and its cause remains unknown, treatment … Continue reading →

Currently available Parkinson’s disease treatments, while capable of improving the early symptoms of the disease, lose their effect as the disease progresses and produce involuntary writing movements in the patients. As of yet there is no cure for the disease, … Continue reading →

International Stem Cell Corp. is tackling some of the world’s most debilitating health maladies with a powerful new stem cell technology that employs parthenogenesis. Parthenogenesis is a type of reproduction that takes place in the absence of fertilization. The company’s … Continue reading →

International Stem Cell Corporation (OTC: ISCO) focuses on utilizing patented human parthenogenetic stem cells (hPSC), developed from unfertilized embryos, to treat Parkinson’s, retinal, and liver diseases where replacing dead and dying cells with new ones seems most effective. However, the … Continue reading →

The true forefront in medicine today is a broad offensive where medical and research professionals are now pulling out all the stops in a never-ending war against broad-spectrum degenerative diseases like cancer or degenerative diseases of specific tissues, such as … Continue reading →

International Stem Cell Corp. this morning posted a business update along with operating results for the three- and nine-month periods ended September 30, 2105. Among other results, the California-based biotech company reported an increase in quarterly revenues, along with significantly … Continue reading →

The ethical controversy surrounding stem cell research does not reach the International Stem Cell Corp. as it employs non-embryonic cells (unfertilized) for exploring and attempting to treat different diseases. The company has developed the first collection of non-embryonic human stem … Continue reading →

California-based International Stem Cell Corporation this morning announced that its wholly owned subsidiary, Cyto Therapeutics, has signed a Letter of Intent (LOI) with Royal Melbourne Hospital in Australia to conduct phase I/IIa clinical trials of ISCO’s proprietary human parthenogenetic neural … Continue reading →

A leader in regenerative medicine, International Stem Cell Corp. uses its parthenogenesis stem cell technology to address immune rejection and self-renewing cells. This technology uses unfertilized eggs that have cells with a duplicate set of human leukocyte antigen genes (HLA) … Continue reading →